SCHEMBL3570310

SCHEMBL3570310

CC(C)(C)OC(=O)Nc1ccc2c3c(cc([N+](=O)[O-])c2c1)NCC3CCl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 1/20 0.38
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA9 Q16790 1/20 0.37
MEN1 O00255 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
ALDH1A1 P00352 1/20 0.35
BRD4 O60885 2/20 0.35
CREBBP Q92793 2/20 0.35
MMP1 P03956 2/20 0.34
MMP2 P08253 2/20 0.34
MMP9 P14780 2/20 0.34
MMP8 P22894 2/20 0.34
MMP13 P45452 2/20 0.34
CYP17A1 P05093 1/20 0.34
EPHX2 P34913 1/20 0.34
PRMT1 Q99873 1/20 0.34
RORC P51449 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13853540 0.79 CYP1A2 (0.31)
SCHEMBL3558308 0.78 ADH1A (0.36) SIRT2RORC
Hydrochloric Acid SCHEMBL3560929 0.74 KMT2A (0.36) MEN1NPC1RAB9AKMT2AALDH1A1
SCHEMBL3563974 0.74 CTSB (0.41) SIRT2MEN1NPC1RAB9AKMT2A
SCHEMBL3564884 0.73 VCAM1 (0.36) KMT2AALDH1A1BCL2
SCHEMBL13345004 0.72 TSHR (0.38) MEN1KMT2AALDH1A1
SCHEMBL3565777 0.70 KMT2A (0.38) MEN1NPC1RAB9AKMT2AALDH1A1
SCHEMBL1181428 0.69 MEN1 (0.58) MEN1NPC1RAB9AKMT2AALDH1A1
SCHEMBL13369288 0.69
SCHEMBL7448057 0.68 ALDH1A1 (0.48) CA12CA1CA9MEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7718688-B2 Nitrobenzindoles and their use in cancer therapy AUCKLAND UNISERVICES LIMITED (NZ) 2010-05-18 US disclosed
US-20080119442-A1 as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization AUCKLAND UNISERVICES LIMITED (NZ) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119442-A1 as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization HIF1AN, HYOU1, HIF1A SIRT2 279/4885CA12 1403/4885CA1 612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.